Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anandan

Showing results (901-910 of 920) with videos related to

Pageof 92
Sort By:
ACS Medicinal Chemistry Letters|November 19, 2021
Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase InhibitorsDerun Li, Hongjun Zhang, Thomas W Lyons, et al.
ACS Medicinal Chemistry Letters|September 16, 2021
Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-OncologyMin Lu, Hongjun Zhang, Derun Li, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer ImmunotherapyMatthew J Mitcheltree, Derun Li, Abdelghani Achab, et al.
Bioorganic & Medicinal Chemistry Letters|January 8, 2011
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemiaSampath-Kumar Anandan, Heather Kay Webb, Dawn Chen, et al.
BMC Medical Research Methodology|February 19, 2013
Protocol for a systematic review and individual patient data meta-analysis of prognostic factors of foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS)Fay Crawford, Chantelle Anandan, Francesca M Chappell, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of DyslipidemiaAnandan Palani, Ashwin U Rao, Xiao Chen, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Discovery of MK-8318, a Potent and Selective CRTh2 Receptor Antagonist for the Treatment of AsthmaXianhai Huang, Jason Brubaker, Wei Zhou, et al.
BMJ Open Respiratory Research|April 8, 2021
Symptomatic, biochemical and radiographic recovery in patients with COVID-19Patrick Mallia, Jamilah Meghji, Brandon Wong, et al.
Advanced Healthcare Materials|May 29, 2025
Immunosuppressive Formulations for Immunological Defense against Traumatic Brain InjuryKelly Lintecum, Abhirami Thumsi, Kara Dunn, et al.
The Journal of Infectious Diseases|March 3, 2022
Cost of Illness Due to Severe Enteric Fever in IndiaDilesh Kumar, Atul Sharma, Saroj Kumar Rana, et al.
Pageof 92

Showing results (901-910 of 920) with videos related to

Sort By:
Pageof 92
ACS Medicinal Chemistry Letters|November 19, 2021
Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase InhibitorsDerun Li, Hongjun Zhang, Thomas W Lyons, et al.
ACS Medicinal Chemistry Letters|September 16, 2021
Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-OncologyMin Lu, Hongjun Zhang, Derun Li, et al.
ACS Medicinal Chemistry Letters|April 16, 2020
Discovery and Optimization of Rationally Designed Bicyclic Inhibitors of Human Arginase to Enhance Cancer ImmunotherapyMatthew J Mitcheltree, Derun Li, Abdelghani Achab, et al.
Bioorganic & Medicinal Chemistry Letters|January 8, 2011
1-(1-acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemiaSampath-Kumar Anandan, Heather Kay Webb, Dawn Chen, et al.
BMC Medical Research Methodology|February 19, 2013
Protocol for a systematic review and individual patient data meta-analysis of prognostic factors of foot ulceration in people with diabetes: the international research collaboration for the prediction of diabetic foot ulcerations (PODUS)Fay Crawford, Chantelle Anandan, Francesca M Chappell, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of DyslipidemiaAnandan Palani, Ashwin U Rao, Xiao Chen, et al.
ACS Medicinal Chemistry Letters|July 24, 2018
Discovery of MK-8318, a Potent and Selective CRTh2 Receptor Antagonist for the Treatment of AsthmaXianhai Huang, Jason Brubaker, Wei Zhou, et al.
BMJ Open Respiratory Research|April 8, 2021
Symptomatic, biochemical and radiographic recovery in patients with COVID-19Patrick Mallia, Jamilah Meghji, Brandon Wong, et al.
Advanced Healthcare Materials|May 29, 2025
Immunosuppressive Formulations for Immunological Defense against Traumatic Brain InjuryKelly Lintecum, Abhirami Thumsi, Kara Dunn, et al.
The Journal of Infectious Diseases|March 3, 2022
Cost of Illness Due to Severe Enteric Fever in IndiaDilesh Kumar, Atul Sharma, Saroj Kumar Rana, et al.
Pageof 92